Successful reduced intensity allogeneic stem cell transplantation for systemic AL amyloidosis

American Journal of Hematology

Volumn 81, Issue 4, 2006, Pages 281-283

  Imamura, Tomoyuki ^a,b   Ogata, Masao ^a   Kohno, Kazuhiro ^a   Tomo, Tadashi ^a   Ohtsuka, Eiichi ^a   Kikuchi, Hiroshi ^b   Kadota, Jun Ichi ^a  

^a Division of Pathogenesis and Disease Control   (Japan)

^b OITA UNIVERSITY   (Japan)

Author keywords

Reduced intensity allogeneic stem cell transplantation; Systemic AL amyloidosis

Indexed keywords

CYCLOSPORIN A; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHOTREXATE; VINCRISTINE;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; AMYLOIDOSIS; ARTICLE; CASE REPORT; DIARRHEA; HEART AMYLOIDOSIS; HUMAN; MALE; NEPHROTIC SYNDROME; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; REMISSION; SYSTEMIC AL AMYLOIDOSIS;

ADULT; AMYLOIDOSIS; DIARRHEA; DRUG THERAPY, COMBINATION; HEART DISEASES; HUMANS; HYPOTENSION; JAPAN; KIDNEY DISEASES; MALE; MELPHALAN; MYELOABLATIVE AGONISTS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REMISSION INDUCTION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 33645723453     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20544     Document Type: Article

References (11)

1. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45-59.
2. Gertz MA, Lacy MQ, Gastineau DA, et al. Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL). Bone Marrow Transplant 2000;26:963-969.
3. Sanchorawala V, Wright DG, Seidin DC, et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant 2001;28:637-642.
4. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002;99:4276-4282.
5. Dispenzieri A, Kyle RA, Lacy MQ, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood 2004;103:3960-3963.
6. Mollee PN, Wechalekar AD, Pereira DL, et al. Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome. Bone Marrow Transplant 2004;33:271-277.
7. Perz JB, Schonland SO, Hundemer M, et al. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single-centre prospective phase II study. Br J Haematol 2004;127:543-551.
8. Guillaume B, Straetmans N, Jadoul M, et al. Allogeneic bone marrow transplantation for AL amyloidosis. Bone Marrow Transplant 1997;20:907-908.
9. Gillmore JD, Davies J, Iqbal A, et al. Allogeneic bone marrow transplantation for systemic AL amyloidosis. Br J Haematol 1998;100:226-228.
10. Kawai Y, Kinoshita K, Arai H, et al. Reduced intensity allogeneic stem cell transplantation for systemic primary amyloidosis refractory to high-dose melphalan. Eur J Haematol 2004;72:448-450.
11. Mehta J, Nagler A, Slavin S. Marrow transplantation in multiple myeloma. N Engl J Med 1992;326:1087-1088.